Nanobiotix signs €40m deal with EIBA financing agreement with the European Investment Bank will allow the French cancer specialist Nanobiotix to borrow up to €40m through loan – money the company needs to boost its research, development … more ➔
CRISPR & Co are GMOs, says EU courtThe EU Court of Justice has ruled that plants created using novel genome editing methods will be classed as genetically modified organisms and therefore have to follow the strict EU guidelines for G … more ➔
Nabriva nabs market-ready antibioticIrish Nabriva Therapeutics plc has acquired San Diego-based antibiotics developer Zavante Therapeutics for 8.2 million shares plus US$97.5m in milestone payments. more ➔
TxCell snapped up by SangamoUS gene editing expert Sangamo Therapeutics is set to acquire French biotech TxCell in an all-cash buyout of €72m on a debt- and cash-free basis. more ➔
Sobi in €387m orphan drug deal with Novi...Swedish Orphan Biovitrum AB (Sobi) has signed a €387 deal with Swiss drug developer Novimmune for a late stage antibody targeting a rare haematology disorder. more ➔
Novartis pays €945m for eczema programmeEuropean biotechs Morphosys and Galapagos have handed over their joint atopical dermatitis programme MOR106 to Novartis for up to €945m. The Swiss pharma giant aims to strengthen its commitment to … more ➔
IMI to spur on antibiotics research amidst...The Innovative Medicines Initiative has launched a new Antimicrobial Resistance Accelerator Programme after Novartis announced its retreat from antibiotics research only days ago. more ➔
Roche granted breakthrough status for live...Roche announced today that the US-American Food and Drug Administration FDA has granted Breakthrough Therapy designation for the Swiss pharma giants mAb combination therapy for liver cancer. more ➔
Epigenetic biomarkers predict immunotherap...UK biotech Oxford BioDynamics has presented data showing that the companys blood test can predict patient response to treatment with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1. more ➔
Urovant launches US$150m IPOSwiss biopharma company Urovant Sciences has launched its IPO on Nasdaq, seeking US$150m. The proceeds will go to Phase III trials for its overactive bladder treatment candidate vibegron. more ➔
